Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2026-01-11 @ 2:35 PM
Study NCT ID:
NCT02841605
Status:
UNKNOWN
Last Update Posted:
2016-07-22
First Post:
2016-07-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enteric Nervous System in Alzheimer Disease
Sponsor:
Nantes University Hospital
Organization:
Study Overview
Official Title:
Enteric Nervous System in Alzheimer Disease
Status:
UNKNOWN
Status Verified Date:
2016-07
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ENTEROMA
Brief Summary:
The close homology between the central and enteric nervous systems suggests that a disease process affecting the central nervous system could also involve its enteric counterpart. The investigators have recently shown in that the enteric neurons can be readily analyzed using routine colonic biopsies. This led us to propose that the enteric nervous system could represent a unique window to assess the neuropathology in living patients with a neurodegenerative disorder. The investigators have already used this approach to show that Parkinson's disease pathology was recapitulated in a single colonic biopsy. By contrast to Parkinson's disease, the detection of Alzheimer's disease (AD) pathology in the enteric neurons has so far failed. This may be due to the low number of human tissue samples in addition to the low sensitivity of the immunohistochemical methods that were used. The aim of the current research project will be therefore to reevaluate AD pathology in a large number of human colonic samples using both a morphological and biochemical approach .
The enteric nervous system could represent a unique window to assess the neuropathology in living patients with AD. This might open the way to the development of novel AD biomarkers that will directly assess the neuropathological process.
Main Aim : To Analyze the presence of beta-amyloid pathology in the enteric nervous system (ENS) in AD patients
Secondary Aim(s):
1. To analyze and describe the presence of tau in the enteric nervous system (ENS) in AD patients
2. To assess neuronal loss in submucosal tissue in AD patients.
3. To examine Glia cells in the enteric nervous system in AD patients..
The enteric nervous system could represent a unique window to assess the neuropathology in living patients with AD. This might open the way to the development of novel AD biomarkers that will directly assess the neuropathological process.
Main Aim : To Analyze the presence of beta-amyloid pathology in the enteric nervous system (ENS) in AD patients
Secondary Aim(s):
1. To analyze and describe the presence of tau in the enteric nervous system (ENS) in AD patients
2. To assess neuronal loss in submucosal tissue in AD patients.
3. To examine Glia cells in the enteric nervous system in AD patients..
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: